Skip to main content
Fig. 5 | Skeletal Muscle

Fig. 5

From: A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice

Fig. 5

GDF11PRO-Fc induces skeletal muscle hypertrophy in dystrophic mdx mice. 6-week-old mdx mice were treated with AAV9-GDF11PRO-Fc (n = 7), AAV9-GDF11PRO-Fc D122A (n = 7), or vehicle (n = 7) via tail vein injection. Mice were euthanized 12 weeks post-treatment. a Representative gross hindlimb musculature. b Wet tissue weight of limb muscles, diaphragm, and heart. c Representative immunofluorescence images of gastrocnemius cross-sections stained with AlexaFluor-488-conjugated WGA to visualize myofibers. Scale bars represent 100 μm. d Average myofiber cross-section area in the gastrocnemius. e Myofiber MFD distribution in the gastrocnemius. A minimum of 500 myofibers were measured per mouse. f Identification of GDF11PRO-Fc by western blot in liver tissue lysate and serum of mice treated with AAV9-GDF11PRO-Fc. Equal protein loading was verified by Ponceau S staining and GAPDH was used as a loading control in liver tissue lysates. *p < 0.05; **p < 0.01; ***p < 0.001; n.s. not significant; compared to vehicle-treated control

Back to article page

Skeletal Muscle

ISSN: 2044-5040

Contact us